Introduction: Erysipelas is a common, ubiquitous bacterial infection of the skin mainly caused by Streptococcus pyogenes - group A beta-hemolytic streptococcus. The current epidemiology of the disease demonstrates an upward trend in cases with primary and recurrent erysipelas, a change in the site of predilection – from face to lower limbs, and an increase of severe cases with a hemorrhagic or bullous-hemorrhagic component. To date, the alterations in hemostasis due to streptococcal bacterial infection are still not well defined. Despite the advanced treatment of erysipelas, in approximately 10% of patients with hemorrhagic and bullous-hemorrhagic erysipelas, a skin necrosis has occurred. The combination of severe types of erysipelas with local and general predisposing factors such as diabetes mellitus, obesity, chronic vessel insufficiency results in recurrences and complications with high percentage of disability. In addition, streptococcal infections may have fulminant progression as for every 1 hour delay of adequate treatment, the percent of mortality increases with 7.5%.
Aim: The purpose of this paper is to establish the current concepts and observations of hemostatic changes in erysipelas.
Materials and Methods: Literature referred in MEDLINE, Web of Science, Scopus
has been studied.
Results: The hemostasis changes in erysipelas are not well researched. The available literature is insufficient as the studies are based on a small number of patients, which prevents any significant conclusions.
Conclusion: The increasing incidence of patients with severe form of erysipelas stresses the need to intensify the study of hemostasis in erysipelas. Knowing the mechanisms of coagulation changes might help to predict and prevent severe, irreversible complications.
Michael Y, Shaukat NM. Erysipelas. [Updated 2019 Dec 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532247/.
Inghammar M, Rasmuussen M, Linder A. Recurrent erysipelas – risk factors and clinical presentations. BMC Infect Dis. 2014;14:270. doi: 10.1186/1471-2334-14-270.
Marina S, Kirov G. Erysipelas. Computer Art. 1992. pp. 46-9. (In Bulgarian).
Pаhlman LI, Malmström E, Mörgelin M, Herwald H. M protein from Streptococcus pyogenes induces tissue factor expression and pro-coagulant activity in human monocytes. Microbiology. 2011; 153(Pt. 8): 2458–64. doi: 10.1099/mic.0.2006/003285-0.
Metzgar D, Zampolli A. The M-protein of group A streptococcus is a key virulence factor and a clinically relevant strain identification marker. Virulence. 2011; 2(5):402-12. doi: 10.4161/viru.2.5.16342.
Shannon O, Herwald H, Oehmcke S. Modulation of the coagulation system during severe streptococcal disease. Curr Top Microbiol Immunol. 2013; 368:189-205. doi: 10.1007/82_2012_283.
Hynes W, Sloan M. Secreted extracellular virulence factors. Streptococcus pyogenes: Basic biology to clinical manifestation. Oklahoma City (OK): University of Oklahoma Health Sciences Center;
pp. 1-22.
Olsen RJ, Shelburne SA, Musser JM. Molecular mechanisms underlying group A streptococcal pathogenesis. Cell Microbiol. 2009; 11(1):1-12. doi: 10.1111/j.1462-5822.2008.01225.x.
Oehmcke S, Shannon O, Mörgelin M, Herwald H. Streptococcal M proteins and their role as virulence determinants. Clin Chim Acta. 2010; 411(17-18):1172–80. doi: 10.1016/j.cca.2010.04.032.
Sun H, Ringdahl U, Homeister JW, Fay WP, Engleberg NC. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science. 2004; 305(5688):1283–6. doi: 10.1126/science.1101245.
Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018; 2(3):549–57. doi: 10.1002/rth2.12109.
Opal S. Interactions between coagulation and inflammation. Scand J Infect Dis. 2003; 35(9):545-54. doi:10.1080/00365540310015638.
Margetic S. Inflammation and haemostasis. Biochemia Medica. 2012; 22(1):49–62.
Nitzsche R, Rosenheinrich M, Kreikemeyer B, Oehmcke-Hecht S. Streptococcus pyogenes triggers activation of the human contact system by streptokinase. Infect Immun. 2015; 83(8):3035–42. doi: 10.1128/IAI.00180-15.
Loof TG, Deicke C, Medina E. The role of coagulation/fibrinolysis during Streptococcus pyogenes infection. Front Cell Infect Microbiol. 2014; 4:128. doi: 10.3389/fcimb.2014.00128.
Chong AY, Blann AD, Lip GYH. Assessment of endothelial damage and dysfunction: Observations in relation to heart failure. QJM - Mon J Assoc Physicians. 2003; 96(4): 253–67. doi:10.1093/qjmed/hcg037.
Periayah MH, Halim AS, Mat Saad AZ. Mechanism action of platelets and crucial blood coagulation pathways in hemostasis. Int J Hematol Oncol Stem Cell Res. 2017; 11(4): 319–27.
Linder A, Johansson l, Thulin P, Hertzén E, Mörgelin M, Christensson B, et al. Erysipelas caused by Group A Streptococcus activates the contact system and induce the release of heparin-binding protein. J Invest Dermatol. 2010; 130(5):1365–72; doi: 10.1038/jid.2009.437.
Inghammar M, Rasmuussen M, Linder A. Recurrent erysipelas – risk factors and clinical presentations. BMC Infect Dis. 2014; 14:270. doi: 10.1186/1471-2334-14-270.
Genev G, Lahtariev St, Stoicheva M, Komitova R, Geneva M. Symptoms and syndromes in infectious diseases. Sofia: Meditsina i fizkultura; 2007. pp. 167-168. (In Bulgarian).
Loof TG, Schmidt O, Herwald H, Theopold U. Coagulation systems of invertebrates and vertebrates and their roles in innate immunity: the same side of two coins? J Innate Immun. 2011; 3(1):34–40. doi: 10.1159/000321641.
Gale JA. Current understanding of hemostasis. Toxicol Pathol. 2011; 39(1):273–80. doi: 10.1177/0192623310389474.
Fokina E. Disfibrinogenemia and hidden hemolysis - indicators of hemorrhagic syndrome in erysipelas. Global J Med R Microbiol Pathol. 2016; 16(1):1-5.
Fokina EG, Gerasimov AN. Prediction degree severity of erysipelas: Risk index of hemorrhagic form of erysipelas. J Infec Dis Treat. 2016; 2:2. doi: 10.21767/2472-1093.100026.
Sjöbring U, Ringdahl U, Ruggeri ZM. Induction of platelet thrombi by bacteria and antibodies. Blood. 2002; 100(13):4470–7. doi: 10.1182/blood-2002-01-0069.
Oehmcke S, Mörgelin M, Malmström J, Linder A, Chew M, Thorlacius H, et al. Stimulation of blood mononuclear cells with bacterial virulence factors leads to the release of pro-coagulant and pro-inflammatory microparticles. Cell Microbiol. 2012; 14(1):107–19. doi: 10.1111/j.1462-5822.2011.01705.x.
Renné T. The procoagulant and proinflammatory plasma contact system. Semin Immunopathol. 2012; 34(1):31–41. doi: 10.1007/s00281-011-0288-2.
Email this article (Login required) 
